R&D

IBM Watson to Boost Pharma R&D and Reduce Costs

IBM Watson to Boost Pharma R&D and Reduce Costs

Written by on September 1, 2014 in Drug Discovery, Research & Development, Uncategorized with 0 Comments

  IBM Watson is taking research to levels of speed unreachable by humans IBM announced last week the next step in Watson Discovery Advisor’s cognitive computing capabilities. Now available as a cloud service, it is already showing its potential to help research teams in all sectors accelerate research and discovery processes, by quickly analysing data […]

Continue Reading

Regenerative medicine: cell therapy for RPE

Regenerative medicine: cell therapy for RPE

Written by on August 25, 2014 in Regenerative Medicine, Research & Development with 0 Comments

Matthew Vincent, Director of Business Development, Advanced Cell Technology joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress  to present on the work of Advanced Cell Technology in the regenerative medicine field. Download this presentation now to find out: Robust Clinical and Preclinical Programs Case study: the Eye Structure of the Retina […]

Continue Reading

Drug Discovery

Leaders of the Antibody sector: An interview with Steve Sazinsky

Leaders of the Antibody sector: An interview with Steve Sazinsky

Written by on August 26, 2014 in Antibodies, Drug Discovery, Featured on app with 0 Comments

The final instalment of Total Biopharma’s interviews with leaders of the Antibody space is with Steve Sazinsky, Senior Scientist of Jounce Therapeutics. Following trend, the interview with Steve Sazinksy details his opinions on the latest developments and challenges that face the industry in the foreseeable future. A key member of the speaker faculty of the […]

Continue Reading

Leaders of the Antibody sector: An interview with Associate Director Mark Chiu, Janssen Research and Development LLC

Leaders of the Antibody sector: An interview with Associate Director Mark Chiu, Janssen Research and Development LLC

Written by on August 19, 2014 in Antibodies, Drug Discovery, Uncategorized with 0 Comments

Following on from our recent interview with Georg Fey, SpectraMab’s CSO, we’ve also had the pleasure of catching up with Mark Chiu, Associate Director of Janssen Research & Development LLC. Total Biopharma chats with Chiu about the latest challenges and upcoming developments within the Antibody sphere. And while Chiu’s answers are specific and straight-to-the-point, if […]

Continue Reading

Clinical Trials

E-Clinical Solution Market Predicted To Reach $5 Billion by 2018

E-Clinical Solution Market Predicted To Reach $5 Billion by 2018

Written by on August 28, 2014 in Clinical Trials, Reports with 0 Comments

A new report by Persistence Market Research has suggested that the global e-clinical solution software market was estimated to grow at a CAGR of 13.8% from 2014 to 2020, indicating significant growth within the sector. The e-clinical solution software market provides software to analyse clinical data, which is ever increasing with more and more clinical […]

Continue Reading

Who You’ll Meet at This Year’s BioPharma Mexico

Who You’ll Meet at This Year’s BioPharma Mexico

Written by on August 21, 2014 in Biosimilars, Clinical Trials, Featured on app, Reports with 0 Comments

BioPharma Mexico is only a few months away, and we’re excited to see you there along with the rest of the Mexican biopharma industry. There’s been a great response so far, with the number of attendees growing every day. Now available is a sample of the attendee list to show you some of the great […]

Continue Reading

Manufacturing

What are the limits of 3D printing in pharma and healthcare?

What are the limits of 3D printing in pharma and healthcare?

Written by on August 27, 2014 in Featured on app, Manufacturing, Reports with 0 Comments

  3D printing has become a common idea across a number of industries, and recently the pharma and healthcare sectors are coming up more and more. There have been some amazing examples recently. One such example is the surgeons in Portugal who, after two failed attempts at surgery on a young boy, replicated a tumour […]

Continue Reading

Moving Towards Personalised Medicine with Big Data Strategies

Moving Towards Personalised Medicine with Big Data Strategies

  The use of Big Data strategies is thought to have the potential to help physicians and scientists move closer to treating individuals, rather than diseases. Developing treatments that are tailored to an individual’s history and sensitivities presents many challenges, and will only be possible within a digital health care system. An article from 20 January […]

Continue Reading

Regulation & Compliance

Stemming The Flow Of Precursor Chemicals from India

Stemming The Flow Of Precursor Chemicals from India

Written by on August 22, 2014 in Regulation and Compliance, Reports with 0 Comments

  According to the 2010 International Narcotics Control Board (INCB) annual report, India is now the major source of diverted precursor chemicals. These chemicals are vital ingredients in the manufacture of narcotics such as amphetamine-type stimulants (ATS), methamphetamine, heroin and cocaine. The control of precursor chemicals is increasingly fundamental to the war against drugs. While precursor control was included in the United […]

Continue Reading

Regulatory updates on Cellular & Tissue-based Products in Japan

Regulatory updates on Cellular & Tissue-based Products in Japan

Masakazu Hirata, MD, PhD, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA) joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Regulatory updates on Cellular & Tissue-based Products in Japan.’ Download this presentation now to find out: Who are the PMDA? Regulatory Authorities in […]

Continue Reading

Pricing & Market Access

Download Ebook: Midsize Indian pharma/biotechs share their insights on the future

Download Ebook: Midsize Indian pharma/biotechs share their insights on the future

Written by on August 28, 2014 in Featured on app, Pricing & Market Access, Reports with 0 Comments

In PharmExec’s 10th Annual Report and Survey of BioPharmaceutical Manufacturing Capacity and Production, India stands as the 4th country preferred by pharmas to outsource manufacturing activities. As India builds its strength in biomanufacturing to become a global hub, we look at four India-based pharmaceutical companies and biotechs that have great potential for development and expansion […]

Continue Reading

Essential Insights: demonstrating drug value in a challenging healthcare market

Essential Insights: demonstrating drug value in a challenging healthcare market

Written by on August 26, 2014 in Featured on app, Pricing & Market Access, Reports with 0 Comments

  How are pharma, payers and patients utilizing evidence of real world outcomes to better understand and demonstrate drug value and improve patient care? How is the global market access environment changing and how is this impacting on pharmaceutical organisations? What does pharma need to know about the diverse payer landscape, alternative payment plans and communicating and […]

Continue Reading

Engagement & Marketing

Patient Opinion Leaders: Andrew Schorr

Written by on September 1, 2014 in Engagement & Communications, Featured on app with 0 Comments

First published on pharmaphorum.com on 8th August 2014, reproduced here by kind permission. As a cancer survivor and passionate patient advocate, Andrew Schorr typifies the concept of a Patient Opinion Leader (POL). He is a contributor to the pharmaphorum report, ‘Patient Opinion Leaders: The new KOLs for pharma?’ In this video he talks about how […]

Continue Reading

Download: The value of non-commercial engagement

Download: The value of non-commercial engagement

Written by on August 20, 2014 in Engagement & Communications, Reports with 0 Comments

At DigiPharm 2013, Shona Davies, Global Communications & Programme Leader Associate Director, Merck gave a presentation on “The value of non-commercial engagement” Download the presentation to learn: What is the business value of a non-commercial engagement Relationships: Customer Engagement Strategies & Permission Defining RoI for non-promotional services What kind of benefit could there possibly be? Download […]

Continue Reading

Partnering & Investment

If You Build It WILL They Come?

If You Build It WILL They Come?

Written by on September 1, 2014 in Partnering & Investment, Regenerative Medicine with 0 Comments

Michael H. May PhD, President & CEO, CCRM joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present  ‘If You Build It WILL They Come?!’ Download this presentation now to find out: CCRM: Background Achievements over the past 30 Months Their Plan to Bridge the Commercialization Gap Stages of the […]

Continue Reading

Been a Partner? What’s Your #PartneringPetPeeve?

Been a Partner? What’s Your #PartneringPetPeeve?

Written by on August 27, 2014 in Orphan Drugs, Partnering & Investment with 0 Comments

In the Pharmaceutical and Biotech industries, partnering and collaborations are a frequent occurrence. Usually, a larger company will utilize a more niche company as a partner for a specific function (CROs and CMOs), or find a smaller drug discovery company that has a compound of interest. This is particularly true in the Orphan Drug industry, […]

Continue Reading

Other Recent Posts

BPTC Shares their Insights on cGMP Manufacturing Using Single-use Bioreactors

The use of production scale, single-use bioreactors for cGMP manufacturing is now an accepted option for production of clinical and even commercial biopharmaceutical products. Early adapters are now routinely using 1,000 – 2,000 L single-use bioreactors to manufacture biopharmaceuticals for use in multiple countries worldwide. As outlined in this whitepaper, single-use bioreactors are being utilized […]

Continue Reading

Download Ebook: Promising  Asian biotechs  to look out for

    We’ve been scouring Asia to find biotechs with the most promising pipelines, and between this ebook and part I (click here to download part I) we think we’ve got them all! Click here to download Promising Asian Biotechs Part II > Read this ebook to learn how you can: Leverage on the latest […]

Continue Reading

Landsteiner’s Francisco Kuri Breña on the Regulation of Biocomparable INN’s

The pathway that goes from fabrication to marketing of biosimilars is designed with safeguards to guarantee their comparability to reference drugs in terms of biochemical properties and clinical effects. In Mexico as in other countries, the law establishes a strict set of requirements in order to obtain marketing approval, which involve head to head comparison […]

Continue Reading

Fisher BioServices Publishes eBook on Commercially Successful Cell Therapies

If you have a cell-based therapy in development, then you need to consider such variables as packaging, storage, inventory management, monitoring systems, distribution, and even clinical site capabilities well before you begin to prepare the Investigational New Drug (IND) submission to the Food and Drug Administration (FDA). By sidestepping these issues until clinical trials begin, […]

Continue Reading

Download: The New Frontier for the Pharmaceutical and Life Sciences Industry- Real Big Value from Big Data

  Technological growth and easy access to sophisticated gadgets have led to a digital data explosion. The life sciences industry is no exception, with its top priority being to improve the quality of human health and well being. Big Data helps achieve this by leveraging innovative techniques to enhance productivity in R&D, and reducing the […]

Continue Reading

Top
Geolocation